vs

Side-by-side financial comparison of CITIUS ONCOLOGY, INC. (CTOR) and Valaris Ltd (VAL). Click either name above to swap in a different company.

Valaris Ltd is the larger business by last-quarter revenue ($5.2M vs $3.9M, roughly 1.3× CITIUS ONCOLOGY, INC.). Valaris Ltd runs the higher net margin — 13798.1% vs -140.3%, a 13938.4% gap on every dollar of revenue.

Citius Oncology, Inc. is a late-stage biopharmaceutical company focused on developing innovative targeted therapies for cancer patients. Its core pipeline covers treatments addressing unmet medical needs in hematologic malignancies and solid tumors, primarily serving North American and global oncology care markets.

Valaris Limited is an offshore drilling contractor headquartered in Houston, Texas, and incorporated in Bermuda. It is the largest offshore drilling and well drilling company in the world. As of February 2025, it owned 52 rigs, including 36 offshore jackup rigs, 11 drillships, and 5 semi-submersible platform drilling rigs.

CTOR vs VAL — Head-to-Head

Bigger by revenue
VAL
VAL
1.3× larger
VAL
$5.2M
$3.9M
CTOR
Higher net margin
VAL
VAL
13938.4% more per $
VAL
13798.1%
-140.3%
CTOR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CTOR
CTOR
VAL
VAL
Revenue
$3.9M
$5.2M
Net Profit
$-5.5M
$717.5M
Gross Margin
80.0%
-7850.0%
Operating Margin
-133.2%
Net Margin
-140.3%
13798.1%
Revenue YoY
405.9%
Net Profit YoY
16.9%
436.6%
EPS (diluted)
$-0.06
$10.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTOR
CTOR
VAL
VAL
Q4 25
$3.9M
$5.2M
Q3 25
$5.6M
Q2 25
$700.0K
Q4 24
$-1.7M
Q3 24
$3.9M
Q2 24
$4.8M
Q1 24
$2.6M
Q4 23
$3.1M
Net Profit
CTOR
CTOR
VAL
VAL
Q4 25
$-5.5M
$717.5M
Q3 25
$188.1M
Q2 25
$115.1M
Q4 24
$133.7M
Q3 24
$64.6M
Q2 24
$149.6M
Q1 24
$25.5M
Q4 23
$828.5M
Gross Margin
CTOR
CTOR
VAL
VAL
Q4 25
80.0%
-7850.0%
Q3 25
-7142.9%
Q2 25
-56428.6%
Q4 24
24529.4%
Q3 24
-11748.7%
Q2 24
-9039.6%
Q1 24
-17007.7%
Q4 23
-12867.7%
Operating Margin
CTOR
CTOR
VAL
VAL
Q4 25
-133.2%
Q3 25
Q2 25
Q4 24
Q3 24
Q2 24
Q1 24
Q4 23
Net Margin
CTOR
CTOR
VAL
VAL
Q4 25
-140.3%
13798.1%
Q3 25
3358.9%
Q2 25
16442.9%
Q4 24
-7864.7%
Q3 24
1656.4%
Q2 24
3116.7%
Q1 24
980.8%
Q4 23
26725.8%
EPS (diluted)
CTOR
CTOR
VAL
VAL
Q4 25
$-0.06
$10.13
Q3 25
$2.65
Q2 25
$1.61
Q4 24
$1.86
Q3 24
$0.88
Q2 24
$2.03
Q1 24
$0.35
Q4 23
$11.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTOR
CTOR
VAL
VAL
Cash + ST InvestmentsLiquidity on hand
$7.3M
$599.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$58.4M
$3.2B
Total Assets
$110.0M
$5.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTOR
CTOR
VAL
VAL
Q4 25
$7.3M
$599.4M
Q3 25
$662.7M
Q2 25
$503.4M
Q4 24
$368.2M
Q3 24
$379.3M
Q2 24
$398.3M
Q1 24
$494.1M
Q4 23
$620.5M
Stockholders' Equity
CTOR
CTOR
VAL
VAL
Q4 25
$58.4M
$3.2B
Q3 25
$2.4B
Q2 25
$2.3B
Q4 24
$2.2B
Q3 24
$2.1B
Q2 24
$2.2B
Q1 24
$2.0B
Q4 23
$2.0B
Total Assets
CTOR
CTOR
VAL
VAL
Q4 25
$110.0M
$5.3B
Q3 25
$4.6B
Q2 25
$4.5B
Q4 24
$4.4B
Q3 24
$4.3B
Q2 24
$4.4B
Q1 24
$4.4B
Q4 23
$4.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTOR
CTOR
VAL
VAL
Operating Cash FlowLast quarter
$-7.4M
$72.2M
Free Cash FlowOCF − Capex
$-34.1M
FCF MarginFCF / Revenue
-655.8%
Capex IntensityCapex / Revenue
2044.2%
Cash ConversionOCF / Net Profit
0.10×
TTM Free Cash FlowTrailing 4 quarters
$159.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTOR
CTOR
VAL
VAL
Q4 25
$-7.4M
$72.2M
Q3 25
$198.1M
Q2 25
$120.0M
Q4 24
$124.6M
Q3 24
$193.0M
Q2 24
$11.5M
Q1 24
$26.3M
Q4 23
$96.7M
Free Cash Flow
CTOR
CTOR
VAL
VAL
Q4 25
$-34.1M
Q3 25
$128.3M
Q2 25
$52.8M
Q4 24
$12.9M
Q3 24
$111.1M
Q2 24
$-98.7M
Q1 24
$-125.0M
Q4 23
$-366.3M
FCF Margin
CTOR
CTOR
VAL
VAL
Q4 25
-655.8%
Q3 25
2291.1%
Q2 25
7542.9%
Q4 24
-758.8%
Q3 24
2848.7%
Q2 24
-2056.3%
Q1 24
-4807.7%
Q4 23
-11816.1%
Capex Intensity
CTOR
CTOR
VAL
VAL
Q4 25
2044.2%
Q3 25
1246.4%
Q2 25
9600.0%
Q4 24
-6570.6%
Q3 24
2100.0%
Q2 24
2295.8%
Q1 24
5819.2%
Q4 23
14935.5%
Cash Conversion
CTOR
CTOR
VAL
VAL
Q4 25
0.10×
Q3 25
1.05×
Q2 25
1.04×
Q4 24
0.93×
Q3 24
2.99×
Q2 24
0.08×
Q1 24
1.03×
Q4 23
0.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons